Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • About
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Anaplastic Lymphoma Kinase-positive”

192 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 192 results

Testing effectiveness (Phase 2)UnknownNCT04796857
What this trial is testing

Tislelizumab in Combination With Lenalidomide in Refractory and Relapsed Elderly Patients With Non-GCB DLBCL

Who this might be right for
Non-GCB/ABC Diffuse Large B-Cell LymphomaHigh-grade B-cell LymphomaFollicular Lymphoma Grade IIIb+3 more
Huiqiang Huang 30
Early research (Phase 1)UnknownNCT03130881
What this trial is testing

Phase I Study of a Selective ALK Inhibitor PLB1003 in Patients With ALK+ NSCLC.

Who this might be right for
Non-Small Cell Lung Cancer
Beijing Pearl Biotechnology Limited Liability Company 60
Not applicableLooking for participantsNCT07374614
What this trial is testing

Iruplinalkib in ALK-Positive Advanced Lung Adenocarcinoma After Lorlatinib

Who this might be right for
Non-Small Cell Lung CancerALKIruplinalkib+3 more
Peking University Shenzhen Hospital 20
Early research (Phase 1)Looking for participantsNCT07001384
What this trial is testing

Alectinib and Duvelisib in People With Anaplastic Lymphoma Kinase-Positive Anaplastic Large Cell Lymphoma (ALK+ALCL)

Who this might be right for
Anaplastic Lymphoma KinaseAnaplastic Large Cell Lymphoma
Memorial Sloan Kettering Cancer Center 30
Early research (Phase 1)Ended earlyNCT03087448
What this trial is testing

Ceritinib + Trametinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer (NSCLC)

Who this might be right for
Non-small Cell Lung Cancer
University of California, San Francisco 9
Large-scale testing (Phase 3)Active Not RecruitingNCT02201992
What this trial is testing

Crizotinib in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been Removed by Surgery and ALK Fusion Mutations (An ALCHEMIST Treatment Trial)

Who this might be right for
ALK Gene RearrangementALK Gene TranslocationALK Positive+5 more
ECOG-ACRIN Cancer Research Group 166
Post-approval studies (Phase 4)UnknownNCT03707847
What this trial is testing

Crizotinib Combined With Etoposide Capsule Followed by Auto-HSCT for Relapsed and Refractory ALK+ ALCL

Who this might be right for
ALK-Positive Anaplastic Large Cell Lymphoma
Mingzhi Zhang 20
Testing effectiveness (Phase 2)Study completedNCT02419287
What this trial is testing

Pilot Study of Crizotinib in Relapsed ALK+ Lymphomas

Who this might be right for
Anaplastic Large Cell Lymphoma, ALK-Positive
University of Milano Bicocca 12
Early research (Phase 1)Looking for participantsNCT06176690
What this trial is testing

Constitutive IL7R (C7R) Modified Banked Allogeneic CD30.CAR EBVSTS for CD30-Positive Lymphomas

Who this might be right for
CD30-Positive Diffuse Large B-Cell LymphomaAnaplastic Large Cell Lymphoma, T Cell and Null Cell TypeAnaplastic Large Cell Lymphoma, ALK-Positive+4 more
Baylor College of Medicine 90
Early research (Phase 1)Study completedNCT01579994
What this trial is testing

Crizotinib and Ganetespib (STA-9090) in ALK Positive Lung Cancers

Who this might be right for
Advanced Lung Cancer
Memorial Sloan Kettering Cancer Center 13
Testing effectiveness (Phase 2)Active Not RecruitingNCT05491811
What this trial is testing

Ensartinib in Combination With Bevacizumab in ALK-positive NSCLC Patients With TP53 Mutation

Who this might be right for
Non-Small Cell Lung Cancer
Sun Yat-sen University 49
Testing effectiveness (Phase 2)Active Not RecruitingNCT05200481
What this trial is testing

Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)

Who this might be right for
Non Small Cell Lung CancerALK Gene Mutation
Intergroupe Francophone de Cancerologie Thoracique 110
Large-scale testing (Phase 3)Study completedNCT01828099
What this trial is testing

LDK378 Versus Chemotherapy in Previously Untreated Patients With ALK Rearranged Non-small Cell Lung Cancer

Who this might be right for
Non-Small Cell Lung Cancer
Novartis Pharmaceuticals 376
Early research (Phase 1)Active Not RecruitingNCT02321501
What this trial is testing

Ceritinib and Everolimus in Treating Patients With Locally Advanced or Metastatic Solid Tumors or Stage IIIB-IV Non-small Cell Lung Cancer

Who this might be right for
ALK PositiveLocally Advanced Malignant Solid NeoplasmMetastatic Malignant Solid Neoplasm+3 more
M.D. Anderson Cancer Center 37
Testing effectiveness (Phase 2)Looking for participantsNCT06378892
What this trial is testing

Evaluate the Combination of Platinum-pemetrexed Based Chemotherapy Plus Lorlatinib in ALK Positive Non-Small Cell Lung Cancer (NSCLC) With Exclusively Extracranial Disease Progression on Lorlatinib

Who this might be right for
Non Small Cell Lung Cancer MetastaticALK Gene Mutation
Centro di Riferimento Oncologico - Aviano 45
Large-scale testing (Phase 3)Not Yet RecruitingNCT06858410
What this trial is testing

Lorlatinib Compared with Concurrent/ Sequential Chemoradiotherapy in Stage III ALK Positive Lung Adenocarcinoma

Who this might be right for
Neoadjuvant Non-Small Cell Lung Cancer
Guangdong Association of Clinical Trials 36
Testing effectiveness (Phase 2)Study completedNCT03909971
What this trial is testing

Lorlatinib in ALK Inhibitor-Treated ALK-Positive NSCLC in China

Who this might be right for
Carcinoma, Non-Small-Cell Lung
Pfizer 109
Large-scale testing (Phase 3)Active Not RecruitingNCT06569420
What this trial is testing

Study Of Comparing SAF-189s With Crizotinib In First Line ALK-Positive Advanced and Metastatic NSCLC

Who this might be right for
Non-Small Cell Lung CancerALK-positiveSAF-189s
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd. 275
Early research (Phase 1)Ended earlyNCT04800822
What this trial is testing

PF-07284892 in Participants With Advanced Solid Tumors

Who this might be right for
Solid Tumor
Pfizer 53
Not applicableNot Yet RecruitingNCT06736561
What this trial is testing

Real-world Clinical Study on the Efficacy and Safety of Ensartinib As Neoadjuvant Treatment for Anaplastic Lymphoma Kinase (ALK) Positive Non-small Cell Lung Cancer (NSCLC) Patients.

Who this might be right for
ALK PositiveEnsartinibNSCLC+1 more
Harbin Medical University 100
Load More Results